These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 11716163)

  • 1. Highlights in lung cancer.
    Brambilla C; Spiro S
    Eur Respir J; 2001 Oct; 18(4):617-8. PubMed ID: 11716163
    [No Abstract]   [Full Text] [Related]  

  • 2. Improving the prognosis for lung cancer patients.
    Clausen MM; Langer SW
    Acta Oncol; 2019 Aug; 58(8):1077-1078. PubMed ID: 31257968
    [No Abstract]   [Full Text] [Related]  

  • 3. BAX and p16INK4A are independent positive prognostic markers for advanced tumour stage of nonsmall cell lung cancer.
    Gessner C; Liebers U; Kuhn H; Stiehl P; Witt C; Schauer J; Wolff G
    Eur Respir J; 2002 Jan; 19(1):134-40. PubMed ID: 11843312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A sensitive immunofluorescence assay for detection of p53 protein in the sputum.
    Feng Z; Tian D; Goldman R
    Methods Mol Med; 2003; 75():389-95. PubMed ID: 12407754
    [No Abstract]   [Full Text] [Related]  

  • 5. Molecular markers help characterize neuroendocrine lung tumors.
    Rusch VW; Klimstra DS; Venkatraman ES
    Ann Thorac Surg; 1996 Sep; 62(3):798-809; discussion 809-10. PubMed ID: 8784011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological markers in non-small cell lung cancer. Retrospective study of 10 year follow-up after surgery.
    Carbognani P; Tincani G; Crafa P; Sansebastiano G; Pazzini L; Zoni R; Bobbio A; Rusca M
    J Cardiovasc Surg (Torino); 2002 Aug; 43(4):545-8. PubMed ID: 12124571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunocytochemical markers in stage I lung cancer: relevance to prognosis.
    Pastorino U; Andreola S; Tagliabue E; Pezzella F; Incarbone M; Sozzi G; Buyse M; Menard S; Pierotti M; Rilke F
    J Clin Oncol; 1997 Aug; 15(8):2858-65. PubMed ID: 9256129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological features and preoperative evaluation of mediastinal nodal status in non-small cell lung cancer.
    Tanaka F; Yanagihara K; Otake Y; Li M; Miyahara R; Wada H; Ito H
    Ann Thorac Surg; 2000 Dec; 70(6):1832-8. PubMed ID: 11156080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Useful prognostic panel markers to express the biological tumor status in resected lung adenocarcinomas.
    Carvalho PE; Antonãngelo L; Bernardi FD; Leão LE; Rodrigues OR; Capelozzi VL
    Jpn J Clin Oncol; 2000 Nov; 30(11):478-86. PubMed ID: 11155917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of NQO1 polymorphism and expression of p53, SOD2, PARP1 in limited-stage small cell lung cancer.
    Kim HC; Song JS; Lee JC; Lee DH; Kim SW; Lee JS; Kim WS; Rho JK; Kim SY; Choi CM
    Int J Clin Exp Pathol; 2014; 7(10):6743-51. PubMed ID: 25400754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor angiogenesis, apoptosis, and p53 oncogene in stage I lung adenocarcinoma.
    Chiba Y; Taniguchi T; Matsuyama K; Sasaki M; Kato Y; Tanaka H; Muraoka R; Tanigawa N
    Surg Today; 1999; 29(11):1148-53. PubMed ID: 10552332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Expression of p53, p21 and bcl-2 in prognosis of lung carcinomas].
    Nhung NV; Mirejovský T; Mirejovský P; Melínová L
    Cesk Patol; 1999 Oct; 35(4):117-21. PubMed ID: 10677910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Orosomucoïd: prealbumin ratio in the monitoring of lung cancer.
    Charet JC; Watine J; Lepretre A; Raimbault C; Charet P
    Clin Biochem; 1996 Jun; 29(3):287-90. PubMed ID: 8740518
    [No Abstract]   [Full Text] [Related]  

  • 14. Prognostic significance of different biomarkers in non-small cell lung cancer.
    Lavezzi AM; Santambrogio L; Bellaviti N; Biondo B; Nosotti M; Radice F; Matturri L
    Oncol Rep; 1999; 6(4):819-25. PubMed ID: 10373663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of nm23 expression in resected pathologic-stage I, non-small cell lung cancer.
    Katakura H; Tanaka F; Oyanagi H; Miyahara R; Yanagihara K; Otake Y; Wada H
    Ann Thorac Surg; 2002 Apr; 73(4):1060-4. PubMed ID: 11996241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p53, c-erbB-2 and nm23 expression have no prognostic significance in primary pulmonary adenocarcinoma.
    MacKinnon M; Kerr KM; King G; Kennedy MM; Cockburn JS; Jeffrey RR
    Eur J Cardiothorac Surg; 1997 May; 11(5):838-42. PubMed ID: 9196297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of p53 and CEA in atypical adenomatous hyperplasia of the lung.
    Pueblitz S; Hieger LR
    Am J Surg Pathol; 1997 Jul; 21(7):867-8. PubMed ID: 9236846
    [No Abstract]   [Full Text] [Related]  

  • 18. Prognostic role of serum p53 antibodies in lung cancer.
    Mattioni M; Soddu S; Prodosmo A; Visca P; Conti S; Alessandrini G; Facciolo F; Strigari L
    BMC Cancer; 2015 Mar; 15():148. PubMed ID: 25884692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis.
    Steels E; Paesmans M; Berghmans T; Branle F; Lemaitre F; Mascaux C; Meert AP; Vallot F; Lafitte JJ; Sculier JP
    Eur Respir J; 2001 Oct; 18(4):705-19. PubMed ID: 11716177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TGF-beta and p53 staining in CT-guided and endoscopic ultrasound fine-needle aspirates of pancreatic adenocarcinoma.
    Sears D; Erickson RA; Sayage-Rabie L; Escobar MC
    Dig Dis Sci; 2004 May; 49(5):828-32. PubMed ID: 15259505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.